Using PET imaging to study tau pathology in older adults
Tau Positron Emission Tomography (PET) in Imaging and Cognition
Columbia University · NCT03372317
This study is testing a special imaging technique to see if tau buildup in the brains of older adults, both healthy and those with mild cognitive issues, affects their thinking and memory skills.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 105 (estimated) |
| Ages | 55 Years to 90 Years |
| Sex | All |
| Sponsor | Columbia University (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT03372317 on ClinicalTrials.gov |
What this trial studies
This observational study aims to utilize the PET radioligand 18F-MK-6240 to detect tau pathology in cognitively healthy older adults and those with mild cognitive impairment (MCI). Researchers will explore the relationship between tau burden and cognitive performance, as well as neural activation patterns observed through functional magnetic resonance imaging (fMRI). The study seeks to understand how tau deposition in specific brain regions may influence cognitive and behavioral outcomes, and its potential role in the risk of cognitive decline and dementia. By examining these interactions, the study hopes to shed light on pre-clinical states of cognitive impairment and protective mechanisms like cognitive reserve.
Who should consider this trial
Good fit: Ideal candidates are adults aged 55-90 who have previously undergone an amyloid PET scan and reside near Columbia University Medical Center.
Not a fit: Patients with contraindications to PET imaging, such as those with metallic implants or significant active physical illnesses, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of tau pathology's role in cognitive decline, potentially leading to early interventions for at-risk individuals.
How similar studies have performed: While studies have explored tau pathology in relation to cognitive decline, this specific approach using 18F-MK-6240 in a pre-clinical population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 55-90 * Previously received an amyloid PET scan * Residing near Columbia University Medical Center * Must be willing and able to participate Exclusion Criteria: * Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour) * Pregnancy * Lactating Women * Current, past, or anticipated exposure to radiation * Significant active physical illness
Where this trial is running
New York, New York
- Columbia University Medical Center — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Yaakov Stern, PhD — Columbia University
- Study coordinator: Reshma Babukutty
- Email: rb2996@cumc.columbia.edu
- Phone: 212-305-6314
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mild Cognitive Impairment, Aging, Tau, MK-6240, Cognition